-
欧美大药企、biotech、VC公司希望引进针对多发性硬化症（MS）的创新药物资产
欢迎感兴趣的药企立即联系药时代BD团队（BD@drugtimes.cn）！
-
US/EU big pharma, biotech and VC companies seeking in‑licensing opportunities for novel therapeutics for Multiple Sclerosis (MS)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team
-
【Asset for Licensing】An Oral VAV1 Molecular Glue with BIC Potential
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
External Collaboration: The Core Engine Behind AbbVie’s Decade-Long Explosive Growth
DrugTimes BD Team has contributed to successful deals with a total value of US$2.3B
-
Amgen’s BD Model: A Benchmark for Cross-Border Biotech Collaboration
DrugTimes BD Team has contributed to successful deals with a total value of US$2.3B
-
27 Assets for Licensing【DrugTimes BD Project】
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
【Asset for Licensing】Orally bioavailable selective THR-β small-molecule agonist for MASH
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
【Asset for Licensing】Novel CD19/BCMA/CD3 trispecific antibody (TsAb) for autoimmune diseases
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
【Asset for Licensing】First-in-class CDH17/4-1BB bispecific antibody (bsAb)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
【Asset for Licensing】Novel LIV-1-targeted ADC armed with optimized TOPO1 inhibitor payload
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
点击查看更多
